Septerna (NASDAQ:SEPN) Releases Quarterly Earnings Results, Misses Estimates By $0.28 EPS

Septerna (NASDAQ:SEPN) released its earnings results on Monday. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.28), Zacks reports. Septerna had a negative net margin of 12,053.03% and a negative return on equity of 31.52%.

Septerna Stock Up 7.7%

NASDAQ:SEPN traded up $1.43 during trading hours on Monday, reaching $19.94. 14,763 shares of the company’s stock were exchanged, compared to its average volume of 576,176. The firm has a market capitalization of $888.80 million and a price-to-earnings ratio of -1.95. Septerna has a 1-year low of $4.17 and a 1-year high of $28.99. The company has a 50-day moving average of $18.71 and a 200 day moving average of $13.40.

Analysts Set New Price Targets

Several research firms have commented on SEPN. HC Wainwright restated a “buy” rating and issued a $26.00 price target on shares of Septerna in a research note on Thursday, August 21st. Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 price target on shares of Septerna in a report on Friday, September 5th. Wall Street Zen downgraded Septerna from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a research note on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $26.75.

Institutional Trading of Septerna

Hedge funds have recently added to or reduced their stakes in the stock. Woodline Partners LP raised its stake in shares of Septerna by 94.2% during the first quarter. Woodline Partners LP now owns 582,585 shares of the company’s stock worth $3,373,000 after purchasing an additional 282,585 shares during the last quarter. Rhumbline Advisers raised its position in Septerna by 16.6% during the 1st quarter. Rhumbline Advisers now owns 23,318 shares of the company’s stock worth $135,000 after buying an additional 3,323 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Septerna by 19.1% in the 2nd quarter. Geode Capital Management LLC now owns 487,956 shares of the company’s stock worth $5,158,000 after acquiring an additional 78,316 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Septerna by 15.0% in the second quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock valued at $107,000 after acquiring an additional 1,315 shares in the last quarter. Finally, CW Advisors LLC acquired a new position in shares of Septerna during the second quarter worth about $133,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.